Exploring causes for declining prostate cancer mortality rates in the United States

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 6, 2008, Pages 627-633

  Colli, Janet L ^a,b   Amling, Christopher L ^a  

^a Alabama   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Ecology; Epidemiology; Prostate cancer; Risk factors; United States

Indexed keywords

CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DIABETES MELLITUS; HEALTH INSURANCE; HUMAN; IMMOBILIZATION; INDEPENDENT VARIABLE; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; SCREENING; UNITED STATES; VITAL STATISTICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; BRACHYTHERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-18; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 55249120997     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.016     Document Type: Article

References (31)

1. Feuer E.J., Merrill R.M., and Hankey B.F. Cancer surveillance series: Interpreting trends in prostate cancer-Part II. Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91 (1999) 1025-1032
2. Surveillance, Epidemiology, and End Results (SEER) Program. Available at www.seer.cancer.gov. SEER*Stat Database: Mortality-All COD, Public-Use With State, Total U.S. (1969-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006. Underlying mortality data provided by NCHS. Available at: www.cdc.gov/nchs.
3. Surveillance, Epidemiology, and End Results (SEER) Program. Available at www.seer.cancer.gov. SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2005 Sub (1973-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
4. Etzioni R., Legler J.M., Feuer E.J., et al. Cancer surveillance series: Interpreting trends in prostate cancer-Part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91 (1999) 1033-1039
5. Shaw P.A., Etzioni R., Zeliadt S.B., et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 160 (2004) 1059-1069
6. Oliver S.E., May M.T., and Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA.". Int J Cancer 92 (2001) 893-898
7. Harris R., and Lohr K.N. Screening for prostate cancer: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 (2002) 917-929
8. Meng M.V., Grossfeld G.D., Sadetsky N., et al. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60 Suppl 1 (2002) 7-11 Discussion 11-2
9. Death data provided by the National Vital Statistics System public use data file. Available at: http://statecancerprofiles.cancer.gov. Accessed August 24, 2006.
10. Centers for Disease Control and Prevention. National Center for Health Statistics. Health Data for All Ages. Available at: http://www.cdc.gov/nchs/healthdataforallages.htm. Accessed September 8, 2006.
11. Weir H.K., Thun M.J., Hankey B.F., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276-1299
12. Jemal A., Ward E., Wu X., et al. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14 (2005) 590-595
13. Hager M.H., Solomon K.R., and Freeman M.R. The role of cholesterol in prostate cancer. Curr Opin Clin Metab Care 9 (2006) 379-385
14. Ma J., Sehgal N.L., Ayanian J.Z., et al. National trends in statin use by coronary heart disease risk category. PLoS Med 2 (2005) e123 Epub 2005 May 31
15. Park C., Lee I., and Kang W.K. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 22 (2001) 1727-1731
16. Zhuang L., Kim J., Adam R.M., et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115 (2005) 959-968
17. Sivaprasad U., Abbas T., and Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5 (2006) 2310-2316
18. Rutishauser J. The role of statins in clinical medicine-LDL-cholesterol lowering and beyond. Swiss Med 136 (2006) 41-49 Review 21
19. Takahashi H.K., Weitz-Schmidt G., Iwagaki H., et al. Hypothesis: The antitumor activities of statins may be mediated by IL-18. J Leukoc Biol 80 (2006) 215-216
20. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: A case-control study. Am J Epidemiol 162 (2005) 318-325
21. Moyad M.A., Merrick G.S., Butler W.M., et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 26 (2006) 298-303
22. Moyad M.A., Merrick G.S., Butler W.M., et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66 (2005) 1150-1154
23. Cyrus-David M.S., Weinberg A., Thompson T., et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: A preliminary report. J Urol 173 (2005) 1923-1925
24. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J. Natl Cancer Inst 24 (2006) 1819-1825
25. Coogan P.F., Palmer J.R., Strom B.L., et al. Statin use and the risk of breast and prostate cancer. Epidemiology 13 (2002) 262-267
26. Nelson D.E., Bland S., Powell-Griner E., et al. State trends in health risk factors and receipt of clinical preventive services among US adults during the 1990s. JAMA 287 (2002) 2659-2667
27. Jordan T.R., Price J.H., King K.A., et al. The validity of male patients' self-reports regarding prostate cancer screening. Prev Med 28 (1999) 297-303
28. Volk R.J., and Cass A.R. The accuracy of primary care patients' self-reports of prostate-specific antigen testing. Am J Prev Med 22 (2002) 56-58
29. de Koning H.J., Auvinen A., Berenguer-Sanchez A., et al. Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal, and ovary cancer trial. Int J Cancer 97 (2002) 237-244
30. Prorok P.C., Andriole G.L., Bresalier R.S., et al. Design of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Control Clin Trials 21 Suppl (2000) 273S-309S
31. Moyad N.A. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: Part I. Urol Oncol 22 (2004) 466-471